An honest answer, and a checklist you can actually use.
Is compounded tirzepatide safe? It depends almost entirely on who prescribes it and which pharmacy prepares it - and both of those are checkable. This page explains what "not FDA-approved" really means, then walks through the verification steps.
Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Zepbound or Mounjaro. Important Safety Information →
644+ patients and counting
TrustpilotCompounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Zepbound or Mounjaro - the FDA does not verify the safety, effectiveness, or quality of compounded drugs. It can, however, be legally prescribed for an individual patient by a licensed provider and prepared by a state-licensed 503A compounding pharmacy. In practice, its safety rests on the legitimacy of that pharmacy and that prescriber, and both are checkable: license lookups are public record, and the verification steps below take minutes. Verification doesn't erase the medication's own risks - tirzepatide has side effects and contraindications a licensed provider must weigh for you (see the Important Safety Information below). Tirzepatide itself is a dual GIP and GLP-1 receptor agonist that lowered appetite and food intake in a clinical trial of the molecule.1
Compounded drugs skip the FDA's pre-market review - no agency has evaluated that specific product's safety, effectiveness, or quality before it reaches you. That is a real difference from an approved drug, and no legitimate program should minimize it. What stands in for that review is the licensing system: state boards of pharmacy overseeing 503A pharmacies, USP compounding standards, and a prescriber who has actually evaluated you. Sourcing is half the safety question for a compounded medication - the other half is the medication itself, which is why a real prescriber evaluation is non-negotiable.
A 503A pharmacy compounds medication for one named patient after a prescription; a 503B outsourcing facility produces larger batches. The distinction decides who oversees the facility and how your medication is made.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Oversight | State board of pharmacy | FDA-registered |
| Prescriptions | One named patient per order | Bulk batches for providers and facilities |
| Standards | USP compounding standards | cGMP manufacturing standards |
One 2026 development worth knowing: in April 2026 the FDA proposed removing tirzepatide and semaglutide from the 503B bulks list, with public comments closed June 29, 2026. The proposal is aimed at bulk production by outsourcing facilities - individual-patient prescriptions filled by a 503A pharmacy are a separate pathway.
Six checks separate a legitimate compounded tirzepatide program from a gray-market seller. All of them are free, and none requires a medical degree.
Any site that sells tirzepatide without a prescription, or approves everyone in minutes, is the single biggest red flag. A legitimate program puts a licensed clinician between you and the medication.
A legitimate program tells you which compounding pharmacy prepares your medication. Look the pharmacy up with the state board of pharmacy where it is licensed - license status is public record.
The National Association of Boards of Pharmacy maintains verification resources and a list of sites it does not recommend. A pharmacy that appears in good standing there is a strong signal.
Prescriptions should come from a U.S.-licensed clinician you can verify through the state medical board. "Doctor-backed" with no name and no license to check is marketing, not medicine.
Tirzepatide is temperature-sensitive. Legitimate pharmacies dispense from U.S. facilities and ship refrigerated. Overseas shipping is a sign you have left the regulated system.
Vials labeled "research use only" or "not for human consumption" are unregulated peptides, not prescription medication. Prices far below the market deserve the same suspicion - published programs run roughly $99 to $297 per month as of July 2026 (see our <a href="/explore/best-compounded-glp-1-telehealth-providers" class="tz-link">provider comparison</a>).
Useful lookups: the FDA's compounding Q&A explains the rules; NABP hosts pharmacy verification resources and state-board contacts.
Nouri runs the model the checklist describes: a U.S.-licensed physician evaluates your health before anything is prescribed, a named, state-licensed 503A pharmacy - see exactly which - compounds each order for you specifically, and everything ships cold-chain from a U.S. facility. The program is one flat price - compounded tirzepatide when prescribed runs $175/mo on the six-month plan ($1,050 every six months), with a nutrition plan and movement plan included. Comparing programs first? See how eight providers stack up in our ranked comparison of compounded GLP-1 telehealth providers.
Begin without the bet.
If you're not satisfied in your first 30 days, you get a full refund - available on the 3-month and 6-month plans. Terms apply →
No. Compounded tirzepatide is not FDA-approved. Compounded drugs are prepared by a licensed pharmacy for an individual patient after a prescription, and they do not go through the FDA review process for safety, effectiveness, or quality that applies to approved drug products. That gap is not a technicality - it is why the pharmacy and prescriber behind a compounded medication matter so much.
No. Compounded tirzepatide is not therapeutically equivalent to the brand-name drugs Zepbound or Mounjaro. It contains tirzepatide and is prepared to order by a state-licensed compounding pharmacy for an individual patient. The FDA does not verify the safety, effectiveness, or quality of compounded drugs.
Yes, through the individual-prescription pathway: a licensed provider prescribes it for a specific patient, and a state-licensed 503A compounding pharmacy prepares it. In April 2026 the FDA proposed excluding tirzepatide and semaglutide from the 503B bulks list - a change aimed at bulk production by outsourcing facilities, not at individual-patient 503A prescriptions.
A 503A pharmacy is licensed by its state board and compounds medication for one named patient at a time, after a prescription, under USP standards. A 503B outsourcing facility registers with the FDA and produces larger batches under cGMP manufacturing standards. Both are legal channels; what matters is that your program tells you which it uses and that the facility's license checks out.
Ask the program which pharmacy dispenses its medication - a legitimate one will tell you. Then look the pharmacy up with the board of pharmacy in its home state (license status is public record) and check NABP's verification resources. If a program will not name its pharmacy, stop there.
No prescription required. "Research use only" or "not for human consumption" labels. An unnamed pharmacy. No verifiable clinician. Overseas shipping. Prices far below the published market. Any one of these is disqualifying - together they describe most of the gray market.
Do not use compounded tirzepatide if you or a family member has a history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Stop use and contact your provider if you experience symptoms of a serious allergic reaction, pancreatitis, or gallbladder problems. Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Talk to your provider about all risks before starting treatment. Compounded tirzepatide is not FDA-approved; the FDA does not verify the safety, effectiveness, or quality of compounded drugs. Read full Important Safety Information →
If the checklist gave you a clearer picture, the next step is simple: read how The Program works, or start the questionnaire and let a physician decide whether it's appropriate for you.
See if you qualifyThe study cited is of the tirzepatide molecule, not compounded tirzepatide, which is not FDA-approved and is not therapeutically equivalent to Zepbound or Mounjaro. Important Safety Information →